 Albireo Pharma Inc NASDAQ: ALBO has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay odevixibat and advancement in the characterization of A3907 in adult liver disease. Data will be presented at the EASL International Liver Congress 2021. 